Brief Article
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Sep 14, 2013; 19(34): 5706-5712
Published online Sep 14, 2013. doi: 10.3748/wjg.v19.i34.5706
Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers
Masaki Takayama, Shigenaga Matsui, Masanori Kawasaki, Yutaka Asakuma, Toshiharu Sakurai, Hiroshi Kashida, Masatoshi Kudo
Masaki Takayama, Shigenaga Matsui, Masanori Kawasaki, Yutaka Asakuma, Toshiharu Sakurai, Hiroshi Kashida, Masatoshi Kudo, Department of Gastroenterology and Hepatology, Kinki University, Osaka 589-8511, Japan
Author contributions: Takayama M and Matsui S contributed equally to this work; Takayama M, Matsui S, Kawasaki M, Asakuma Y, Sakurai T, Kashida H and Kudo M designed the research; Takayama M and Matsui S performed the research; Takayama M and Matsui S analyzed the data; Takayama M wrote the paper.
Correspondence to: Masaki Takayama, MD, Department of Gastroenterology and Hepatology, Kinki University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan. masaki0742@yahoo.co.jp
Telephone: +81-72-3660221 Fax: +81-72-3672880
Received: June 9, 2013
Revised: July 25, 2013
Accepted: August 8, 2013
Published online: September 14, 2013
Processing time: 135 Days and 20.7 Hours
Core Tip

Core tip: In this prospective randomized, parallel-controlled study, we demonstrated that rebamipide monotherapy was as effective as proton-pump inhibitor (PPI) in the healing of endoscopic submucosal dissection-induced ulcers, regardless of the location of the resected cancer, the degree of atrophic gastritis, or the presence of Helicobacter pylori infection. In addition, rebamipide treatment is more cost-effective and results in a better quality of ulcer healing compared with the PPI lansoprazole.